Tags

Type your tag names separated by a space and hit enter

Vipera berus berus Venom from Russia: Venomics, Bioactivities and Preclinical Assessment of Microgen Antivenom.
Toxins (Basel). 2019 02 01; 11(2)T

Abstract

The common European adder, Vipera berus berus, is a medically relevant species, which is widely distributed in Russia and thus, is responsible for most snakebite accidents in Russia. We have investigated the toxic and enzymatic activities and have determined the proteomic composition of its venom. Phospholipases A2 (PLA₂, 25.3% of the venom proteome), serine proteinases (SVSP, 16.2%), metalloproteinases (SVMP, 17.2%), vasoactive peptides (bradykinin-potentiating peptides (BPPs), 9.5% and C-type natriuretic peptides (C-NAP, 7.8%), cysteine-rich secretory protein (CRISP, 8%) and L-amino acid oxidase (LAO, 7.3%) represent the major toxin classes found in V. b. berus (Russia) venom. This study was also designed to assess the in vivo and in vitro preclinical efficacy of the Russian Microgen antivenom in neutralizing the main effects of V. b. berus venom. The results show that this antivenom is capable of neutralizing the lethal, hemorrhagic and PLA₂ activities. Third-generation antivenomics was applied to quantify the toxin-recognition landscape and the maximal binding capacity of the antivenom for each component of the venom. The antivenomics analysis revealed that 6.24% of the anti-V. b. berus F(ab')2 molecules fraction are toxin-binding antibodies, 60% of which represent clinically relevant antivenom molecules.

Links

PMC Free PDF

Authors+Show Affiliations

Al-Shekhadat RI
LLC Innova Plus, Saint-Petersburg 198099, Russia. ceo@innovaplus.ru.
Lopushanskaya KS
LLC Innova Plus, Saint-Petersburg 198099, Russia. ghevachka@mail.ru.
Segura Á
Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501-206, Costa Rica. alvaro.seguraruiz@ucr.ac.cr.
Gutiérrez JM
Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501-206, Costa Rica. jose.gutierrez@ucr.ac.cr.
Calvete JJ
Laboratorio de Venómica Evolutiva y Traslacional, CSIC, Jaime Roig 11, 46010 Valencia, Spain. jcalvete@ibv.csic.es.
Pla D
Laboratorio de Venómica Evolutiva y Traslacional, CSIC, Jaime Roig 11, 46010 Valencia, Spain. dpla@ibv.csic.es.

MeSH

AnimalsAntiveninsFemaleL-Amino Acid OxidaseMaleMetalloproteasesMicePeptidesPhospholipases A2RussiaSerine ProteasesViper VenomsViperidae

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30717298

Citation

Al-Shekhadat, Ruslan I., et al. "Vipera Berus Berus Venom From Russia: Venomics, Bioactivities and Preclinical Assessment of Microgen Antivenom." Toxins, vol. 11, no. 2, 2019.
Al-Shekhadat RI, Lopushanskaya KS, Segura Á, et al. Vipera berus berus Venom from Russia: Venomics, Bioactivities and Preclinical Assessment of Microgen Antivenom. Toxins (Basel). 2019;11(2).
Al-Shekhadat, R. I., Lopushanskaya, K. S., Segura, Á., Gutiérrez, J. M., Calvete, J. J., & Pla, D. (2019). Vipera berus berus Venom from Russia: Venomics, Bioactivities and Preclinical Assessment of Microgen Antivenom. Toxins, 11(2). https://doi.org/10.3390/toxins11020090
Al-Shekhadat RI, et al. Vipera Berus Berus Venom From Russia: Venomics, Bioactivities and Preclinical Assessment of Microgen Antivenom. Toxins (Basel). 2019 02 1;11(2) PubMed PMID: 30717298.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vipera berus berus Venom from Russia: Venomics, Bioactivities and Preclinical Assessment of Microgen Antivenom. AU - Al-Shekhadat,Ruslan I, AU - Lopushanskaya,Ksenia S, AU - Segura,Álvaro, AU - Gutiérrez,José María, AU - Calvete,Juan J, AU - Pla,Davinia, Y1 - 2019/02/01/ PY - 2018/12/31/received PY - 2019/01/27/revised PY - 2019/01/29/accepted PY - 2019/2/6/entrez PY - 2019/2/6/pubmed PY - 2019/12/31/medline KW - Vipera berus berus KW - antivenomics. KW - common European viper KW - snake antivenom KW - snake venom KW - venomics JF - Toxins JO - Toxins (Basel) VL - 11 IS - 2 N2 - The common European adder, Vipera berus berus, is a medically relevant species, which is widely distributed in Russia and thus, is responsible for most snakebite accidents in Russia. We have investigated the toxic and enzymatic activities and have determined the proteomic composition of its venom. Phospholipases A2 (PLA₂, 25.3% of the venom proteome), serine proteinases (SVSP, 16.2%), metalloproteinases (SVMP, 17.2%), vasoactive peptides (bradykinin-potentiating peptides (BPPs), 9.5% and C-type natriuretic peptides (C-NAP, 7.8%), cysteine-rich secretory protein (CRISP, 8%) and L-amino acid oxidase (LAO, 7.3%) represent the major toxin classes found in V. b. berus (Russia) venom. This study was also designed to assess the in vivo and in vitro preclinical efficacy of the Russian Microgen antivenom in neutralizing the main effects of V. b. berus venom. The results show that this antivenom is capable of neutralizing the lethal, hemorrhagic and PLA₂ activities. Third-generation antivenomics was applied to quantify the toxin-recognition landscape and the maximal binding capacity of the antivenom for each component of the venom. The antivenomics analysis revealed that 6.24% of the anti-V. b. berus F(ab')2 molecules fraction are toxin-binding antibodies, 60% of which represent clinically relevant antivenom molecules. SN - 2072-6651 UR - https://www.unboundmedicine.com/medline/citation/30717298/Vipera_berus_berus_Venom_from_Russia:_Venomics_Bioactivities_and_Preclinical_Assessment_of_Microgen_Antivenom_ DB - PRIME DP - Unbound Medicine ER -